P-Glycoprotein Interactions: Bupropion and Sertraline at the Blood-Brain Barrier
Direct Answer to P-gp Status
Bupropion and its major metabolites have very weak affinity for P-glycoprotein and are not clinically relevant P-gp substrates or modulators, whereas sertraline and its metabolite desmethylsertraline are high-affinity P-gp substrates. 1
Bupropion's P-gp Profile
Bupropion shows negligible P-gp interaction, with Vmax/Km values lower than 0.01 min⁻¹ × 10⁻³, which is approximately 160-fold weaker than verapamil (a known P-gp substrate) 1
The three major metabolites of bupropion (threo-amino alcohol, erythro-amino alcohol, and hydroxybupropion) similarly demonstrate very weak P-gp affinity 1
Bupropion crosses the blood-brain barrier rapidly through passive diffusion rather than P-gp-mediated transport, achieving brain extracellular fluid/plasma unbound concentration ratios of 1.9, indicating net uptake asymmetry independent of P-gp 2
Sertraline's P-gp Profile
Sertraline functions as a high-affinity P-gp substrate with Vmax/Km values of 1.6 min⁻¹ × 10⁻³, comparable to verapamil (1.7 min⁻¹ × 10⁻³) 1
Desmethylsertraline, the active metabolite, also demonstrates high P-gp affinity (Vmax/Km = 1.4 min⁻¹ × 10⁻³) 1
P-glycoprotein at the blood-brain barrier normally limits CNS penetration of sertraline through ATP-dependent efflux at the luminal membrane of brain capillary endothelial cells 3
Co-Administration Effects at the Blood-Brain Barrier
When sertraline and bupropion reach the blood-brain barrier simultaneously, no direct P-gp-mediated competition occurs because bupropion does not interact meaningfully with P-gp. 1
Mechanistic Considerations:
Sertraline's brain penetration is actively restricted by P-gp efflux pumps on the luminal (blood-facing) surface of brain endothelial cells, which continuously pump sertraline back into the bloodstream 4, 3
Bupropion crosses the blood-brain barrier independently of P-gp, achieving rapid equilibration through passive mechanisms without competing for P-gp binding sites 1, 2
Since bupropion has Vmax/Km values >160-fold lower than sertraline for P-gp, it cannot functionally inhibit or compete with sertraline's P-gp-mediated efflux even at therapeutic concentrations 1
Metabolic Interactions (Separate from P-gp)
While P-gp interactions are minimal, a metabolic interaction exists:
Sertraline pretreatment modestly increases bupropion metabolism to hydroxybupropion through CYP2B6 induction, increasing the plasma hydroxybupropion-to-bupropion AUC ratio by 27% 5
This metabolic interaction is distinct from P-gp effects and occurs at the hepatic level, not the blood-brain barrier 5
Bupropion increased brain AUC of sertraline by 1.5-fold in animal models, but this effect appears mediated through metabolic enzyme inhibition rather than P-gp modulation 6
Clinical Implications
The absence of P-gp competition between these agents means their co-administration does not create P-gp-mediated drug-drug interactions at the blood-brain barrier. 1
Key Points:
Sertraline's CNS penetration remains limited by P-gp efflux regardless of bupropion presence 3, 1
Bupropion achieves consistent brain penetration unaffected by P-gp status 2
Any observed pharmacokinetic interactions between these drugs stem from CYP enzyme modulation (particularly CYP2B6 and CYP2D6), not P-gp competition 6, 5